Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498899 | 0.91 | SLC6A2 (0.42) | CAPN1SLC6A2CTSBOPRK1REN | |
| SCHEMBL30611006 | 0.90 | CAPN1 (0.44) | CAPN1SLC6A2CTSBOPRK1APLNR | |
| SCHEMBL5533523 | 0.89 | SLC6A2 (0.43) | CAPN1SLC6A2CTSBOPRK1APLNR | |
| SCHEMBL28081211 | 0.89 | SLC6A2 (0.43) | CAPN1SLC6A2CTSBOPRK1APLNR | |
| SCHEMBL5533513 | 0.89 | SLC6A2 (0.43) | CAPN1SLC6A2CTSBOPRK1APLNR | |
| SCHEMBL29608052 | 0.89 | SLC6A2 (0.47) | CAPN1SLC6A2CTSBF2REN | |
| SCHEMBL29555036 | 0.88 | ACE (0.41) | CAPN1OPRK1APLNRF2REN | |
| SCHEMBL29590547 | 0.88 | OPRK1 (0.46) | SLC6A2OPRK1RENACE | |
| SCHEMBL29630560 | 0.88 | OPRK1 (0.46) | SLC6A2OPRK1RENACE | |
| SCHEMBL29608127 | 0.88 | REN (0.49) | CAPN1SLC6A2F2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (OR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | ARGLU1, TPX2, RXFP1 | CAPN1 2929/4885SLC6A2 1923/4885CTSB 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.